文献速递眼底病与葡萄膜炎神经眼科

葡萄膜黑色素瘤患者接受斑块近距离放射治疗后感觉运动并发症的评估

Assessment of Sensorimotor Complications After Plaque Brachytherapy for Patients With Uveal Melanoma.
PubMed 文献 · Am J Ophthalmol · 2025-10-14

这项回顾性单中心临床病例对照研究纳入2014年5月1日至2022年12月1日接受碘-125斑块近距离放射治疗的375例葡萄膜黑色素瘤患者,评估复视和斜视的发生率与特征。术后复视发生率为38.9%(146/375),多数在6个月内自行缓解(71.2%;104/146);斜视记录类型者占7.2%(27/375),感觉剥夺相关斜视发生率为3.7%(14/375)。

要点

  • 碘-125斑块近距离放射治疗后复视发生率为38.9%(146/375),58.2%(85/146)持续不足6个月,71.2%(104/146)自行缓解。
  • 斜视类型有记录者占7.2%(27/375),其中水平成分最常见(74.1%;20/27);感觉剥夺相关斜视发生率为3.7%(14/375)。
  • 上直肌操作(P = .010)、较年轻年龄(P = .045)及中度(P = .022)或重度(P = .045)视力下降与斜视发生 odds 增加相关。

核心结论

  • 碘-125斑块近距离放射治疗葡萄膜黑色素瘤具有中等程度的复视风险,复视通常自行缓解;也可能发生感觉剥夺相关斜视;尽管感觉运动并发症可能出现,但多数在术后6个月内无需干预即可缓解。

研究设计与样本

  • 回顾性单中心临床病例对照研究,纳入2014年5月1日至2022年12月1日接受碘-125斑块近距离放射治疗的葡萄膜黑色素瘤患者,共375例(平均年龄64 ± 14岁;50.4%为女性)。

主要发现

  • 平均随访时间3.68 ± 2.3年;共操作321条肌肉以放置斑块,最常为外直肌(42.1%;135/321),其次为上直肌(22.4%;72/321)和下直肌(17.4%;56/321);最常通过肌肉离断进行(96.3%;309/321)。
  • 术后复视发生于38.9%(146/375)的患者;复视通常持续不足6个月(58.2%;85/146),大多数患者自行缓解(71.2%;104/146)。
  • 共有7.2%(27/375)的患者有斜视类型记录,其中水平成分最常见(74.1%;20/27);感觉剥夺相关斜视的发生率为3.7%(14/375)。
  • 在多变量回归模型中,无因素与复视 odds 增加相关;基线视力较差和肿瘤距视盘距离较大者复视 odds 较低(分别为 P = .005 和 P = .026)。
  • 上直肌操作(P = .010)、较年轻年龄(P = .045)以及中度(P = .022)或重度(P = .045)视力下降与斜视发生 odds 增加相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the incidence and characterization of diplopia and strabismus following treatment with Iodine-125 plaque brachytherapy for uveal melanoma. DESIGN: Retrospective single-center clinical case-control study. PARTICIPANTS: Patients with uveal melanoma treated with Iodine-125 plaque brachytherapy between May 1, 2014 and December 1, 2022. METHODS: A chart review was conducted for patients with uveal melanoma treated with plaque brachytherapy. Data on demographics, tumor characteristics, surgical technique, radiation dosing, and sensorimotor complications were collected. MAIN OUTCOME MEASURES: Data was analyzed to assess the incidence, characteristics, treatment, and outcomes of diplopia and/or strabismus following plaque brachytherapy. Statistical analysis was performed to assess for associations between sensorimotor complications and independent variables. RESULTS: A total of 375 patients (mean age 64 ± 14 years; 50.4% female) were treated with Iodine-125 plaque brachytherapy. Mean follow-up time was 3.68 ± 2.3 years. A total of 321 muscles were manipulated for plaque placement, most commonly the lateral rectus (42.1%; 135/321) followed by the superior rectus (22.4%; 72/321) and inferior rectus (17.4%; 56/321). This was done most often through disinsertion of the muscle (96.3%; 309/321). Postoperative diplopia occurred in 38.9% of patients (146/375). Diplopia typically lasted less than 6 months (58.2%; 85/146) and spontaneous resolution was seen in most patients (71.2%; 104/146). In total, 7.2% (27/375) of the patients had documentation for type of strabismus, with a horizontal component noted most often (74.1%; 20/27). The incidence of sensory-deprivation related strabismus was 3.7% (14/375). In a multivariate regression model, there were no factors associated with increased odds of developing diplopia. Those with worse baseline visual acuity and greater tumor distance from the optic disc had lower odds of diplopia (P = .005 and P = .026, respectively). Superior rectus muscle manipulation (P = .010), younger age (P = .045), and moderate (P = .022) or severe (P = .045) vision loss were associated with increased odds of developing strabismus. CONCLUSIONS: Iodine-125 plaque brachytherapy for uveal melanoma carries a moderate risk of diplopia, which typically resolves on its own. Sensory deprivation-related strabismus may also occur. These findings highlight that although sensorimotor complications may occur, they often resolve within 6 months postoperatively with no intervention.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Munkwitz SE, Shields C, Nicola MD, et al. Assessment of Sensorimotor Complications After Plaque Brachytherapy for Patients With Uveal Melanoma. Am J Ophthalmol. 2025. PMID: 41101577. doi:10.1016/j.ajo.2025.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。